KPV Research Hub · Evidence Overview

KPV research evidence: what has actually been studied?

A structured review of the Lys-Pro-Val tripeptide, with emphasis on intestinal-cell assays, mouse colitis models, and the absence of adequate human trials.

JD BioWorks Research LibraryPublished: July 15, 2026Last reviewed: July 15, 2026Editorial review: JD BioWorks Research Library

Evidence at a glance

Human evidenceNo adequate controlled human efficacy evidence was identified for KPV itself in the literature reviewed here.

Preclinical evidenceCell and mouse studies examine peptide transport, NF-κB/MAPK signaling, cytokine measures, and chemically induced colitis.

Evidence gapHuman pharmacokinetics, safety, formulation performance, and clinical outcomes remain insufficiently characterized.

ScopeResults in cultured intestinal cells or chemically induced mouse colitis do not establish safety or effectiveness in people.

Interpretation note: Findings must stay tied to the exact molecule, formulation, model, population, and endpoint studied. A biological signal is not, by itself, proof of safety or effectiveness.

Overview

KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone. Research has focused on anti-inflammatory signaling and peptide transport, particularly in intestinal epithelial systems. Its small size does not remove the need for identity, purity, stability, and exposure data.

Research background

A frequently cited 2008 study evaluated KPV uptake through the PepT1 transporter in intestinal epithelial and immune-cell systems and in two mouse colitis models. The paper linked uptake to changes in inflammatory signaling and cytokine measures. This is mechanistic and preclinical evidence, not a human efficacy study.

Findings by research area

Research area	What has been reported	What it does not establish
Cell signaling	Nanomolar KPV was reported to affect NF-κB/MAPK activation and cytokine secretion in tested cell systems.	A clinical anti-inflammatory effect.
Transport	Experiments implicated PepT1 in KPV uptake.	Bioavailability across human formulations and routes.
Mouse colitis	Oral KPV reduced selected inflammatory measures in DSS- and TNBS-induced models.	Treatment of human inflammatory disease.

Human evidence

Human data

No adequate randomized human trial of KPV itself was identified in the primary literature used for this summary. Human-derived cell lines are not human clinical evidence. Accordingly, safety, pharmacokinetics, and efficacy in people remain unresolved.

Preclinical evidence

Animal data

The Dalmasso study used DSS- and TNBS-induced mouse colitis models and reported lower histologic and cytokine-related measures with KPV. These are deliberately induced disease models with species-specific transport and immune biology.

Laboratory evidence

In-vitro and analytical context

Caco2-BBE, HT29-Cl.19A, and Jurkat cells were used to investigate transport and signaling. Concentration, transporter expression, inflammatory stimulus, cell lineage, and assay selection all shape the result.

Research limitations

No adequate controlled human outcome trials were identified.
The strongest evidence is mechanistic and preclinical.
Transport and stability can vary by formulation and biological compartment.
Long-term toxicology and immunologic consequences are not established.

Future research

Research priorities include validated analytical methods, stability and transport studies, staged pharmacokinetics and toxicology, and only then appropriately controlled human investigation with predefined outcomes.

Primary references

Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. doi:10.1053/j.gastro.2007.10.026.

Article record

Research question: What does the published evidence on KPV show across human, animal, and laboratory research?
Evidence cutoff: July 15, 2026
Article status: Published educational research summary; not independently peer reviewed
Author: JD BioWorks Research Library
Editorial review: JD BioWorks Research Library
Planned review cycle: At least annually, or sooner if material evidence or regulatory information changes

This article summarizes published research for educational and laboratory-information purposes. It is not medical advice, does not provide instructions for personal use, and does not establish that any material is safe or effective for human or veterinary use.

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the public documentation resources below, then continue to Research Product Access when you are ready to review the gated catalog.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Get Research Product Access Complete the Research Use Acknowledgment to create an account and receive automatic product access.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.